Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

HVIVO PLC Major Shareholding Notification 2016

Jun 20, 2016

7697_dirs_2016-06-20_351b0f16-b60c-4c1d-998c-297c78c81d89.html

Major Shareholding Notification

Open in viewer

Opens in your device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 7406B

Venn Life Sciences Holdings PLC

20 June 2016

Venn Life Sciences Holdings Plc

("Venn" or the "Company")

Shareholder notification

Venn Life Sciences (AIM: VENN), a growing Clinical Research Organisation (CRO) providing a suite of consulting and clinical trial services to pharmaceutical, biotechnology and medical device clients, has been informed today that Mr David Newton no longer holds a notifiable shareholding in the Company.

Enquiries:

Venn Life Sciences Holdings Plc www.vennlifesciences.com
Tony Richardson, Chief Executive Officer Tel: +353 154 99 341
Jonathan Hartshorn, Chief Financial Officer Tel: +353 153 93 269
Aoife O Farrell, Marketing Manager Tel: +353 153 93 269
Davy (Nominated Adviser, ESM Adviser and Joint Broker) Tel: +353 1 679 6363
Fergal Meegan / Matthew DeVere White (Corporate Finance)
Paul Burke (Corporate Broking)
Hybridan LLP (Joint-Broker)
Claire Louise Noyce Tel: 020 3764 2341
Walbrook PR Ltd Tel: 020 7933 8787 or [email protected]
Paul McManus Mob: 07980 541 893
Lianne Cawthorne Mob: 07584 391 303

About Venn Life Sciences Limited: Venn Life Sciences is a Contract Research Organisation providing drug development, clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device organisations. With dedicated operations in France, Germany, the Netherlands, the UK, Ireland and Europe wide representation - Venn Life Sciences specialises in rapid deployment and management of multisite projects, across all phases. Venn Life Sciences also has an innovation division - Innovenn - focused primarily on breakthrough development opportunities in Skin Science.

For more information about the Company, please visit: www.vennlifesciences.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHAKKDDPBKDFAB